research use only
Cat.No.S6758
| Related Targets | HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK |
|---|---|
| Other p300/CBP Inhibitors | A-485 Inobrodib (CCS-1477) Curcumin SGC-CBP30 CPI-637 Histone Acetyltransferase Inhibitor II GNE-049 Anacardic Acid CPI-1612 E7386 |
|
In vitro |
DMSO
: 94 mg/mL
(200.6 mM)
Water : 94 mg/mL Ethanol : 94 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 468.59 | Formula | C27H36N2O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1640282-31-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCC(=O)N1CCOC2=C(C1)C=C(C=C2OCC3CCCN(C3)C)C4=CC(=C(C=C4)OC)OC | ||
| Targets/IC50/Ki |
CBP
(Cell-free assay) 151 nM(Kd)
p300
(Cell-free assay) 167 nM(Kd)
|
|---|---|
| In vitro |
Exposure of human and mouse leukemic cell lines to I-CBP112 resulted in substantially impaired colony formation and induced cellular differentiation without significant cytotoxicity. This compound significantly reduced the leukemia-initiating potential of MLL-AF9+ AML cells in a dose-dependent manner in vitro and in vivo. It is an acetyl-lysine competitive inhibitor displacing H3K56ac from the CBP binding site with an IC50 value of 170 nM. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.